These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19095596)

  • 1. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients.
    Kurian B; Joshi R; Helmuth A
    Endocr Pract; 2008 Nov; 14(8):979-84. PubMed ID: 19095596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplantation diabetes mellitus: evaluation of treatment strategies.
    Haidinger M; Antlanger M; Kopecky C; Kovarik JJ; Säemann MD; Werzowa J
    Clin Transplant; 2015 May; 29(5):415-24. PubMed ID: 25777150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant diabetes mellitus: is it associated with poor allograft outcomes in renal transplants?
    Choi JY; Kwon OJ
    Transplant Proc; 2013 Oct; 45(8):2892-8. PubMed ID: 24156999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function markers and metformin eligibility.
    Tavares Bello C; Castro Fonseca R; Sousa Santos F; Sequeira Duarte J; Azinheira J; Vasconcelos C
    Minerva Endocrinol; 2018 Sep; 43(3):246-252. PubMed ID: 28565889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Preexisting and Post-transplant Diabetes Mellitus on Outcomes Following Liver Transplantation.
    Aravinthan AD; Fateen W; Doyle AC; Venkatachalapathy SV; Issachar A; Galvin Z; Sapisochin G; Cattral MS; Ghanekar A; McGilvray ID; Selzner M; Grant DR; Selzner N; Lilly LB; Renner EL; Bhat M
    Transplantation; 2019 Dec; 103(12):2523-2530. PubMed ID: 30985734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
    Prentice JC; Conlin PR; Gellad WF; Edelman D; Lee TA; Pizer SD
    Value Health; 2014 Dec; 17(8):854-62. PubMed ID: 25498781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of metformin and thiazolidinedione use on lung cancer in diabetics.
    Mazzone PJ; Rai H; Beukemann M; Xu M; Jain A; Sasidhar M
    BMC Cancer; 2012 Sep; 12():410. PubMed ID: 22978440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term impact of pretransplant and posttransplant diabetes mellitus on kidney transplant outcomes.
    Tsai JP; Lian JD; Wu SW; Hung TW; Tsai HC; Chang HR
    World J Surg; 2011 Dec; 35(12):2818-25. PubMed ID: 21976005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
    Lin HC; Hsu YT; Kachingwe BH; Hsu CY; Uang YS; Wang LH
    J Clin Pharm Ther; 2014 Aug; 39(4):354-60. PubMed ID: 24661226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: A retrospective cohort study in a single teaching hospital.
    Fu CP; Lee CL; Li YH; Lin SY
    J Diabetes Investig; 2021 Sep; 12(9):1603-1609. PubMed ID: 33550691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience.
    Xu X; Ling Q; He ZL; Gao F; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):465-70. PubMed ID: 18842490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin.
    Shaya FT; Shin JY; Mullins D; Fatodu HO; Gu A; Saunders E
    J Natl Med Assoc; 2005 Apr; 97(4):493-7. PubMed ID: 15868769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating kidney function and use of oral antidiabetic drugs in elderly.
    Douros A; Ebert N; Jakob O; Martus P; Kreutz R; Schaeffner E
    Fundam Clin Pharmacol; 2015 Jun; 29(3):321-8. PubMed ID: 25817734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin in the Management of Type 2 Diabetes Mellitus After Kidney Transplant.
    Attallah N; Yassine L
    Transplant Proc; 2021 Sep; 53(7):2234-2237. PubMed ID: 34376312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin use in kidney transplant recipients in the United States: an observational study.
    Stephen J; Anderson-Haag TL; Gustafson S; Snyder JJ; Kasiske BL; Israni AK
    Am J Nephrol; 2014; 40(6):546-53. PubMed ID: 25613554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
    Barner JC
    Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.
    Lipscombe LL; Gomes T; Lévesque LE; Hux JE; Juurlink DN; Alter DA
    JAMA; 2007 Dec; 298(22):2634-43. PubMed ID: 18073359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplant diabetes mellitus after kidney transplantation with different immunosuppressive agents.
    Romagnoli J; Citterio F; Violi P; Nanni G; Castagneto M
    Transplant Proc; 2004 Apr; 36(3):690-1. PubMed ID: 15110632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.